Blue Jet Healthcare Limited · NSE:BLUEJET
Blue Jet Healthcare — Q4 FY24 Earnings Presentation
41 slides from Blue Jet Healthcare's earnings presentation, May 27, 2024
Slide 1: Cover letter to stock exchanges: Analysts/Investors Presentation
(is) BLUE JET HEALTHCARE LIMITED REGISTERED & CORPORATE : 701 & 702, BHUMIRAJ COSTARICA, PLOT1 & 2, SECTOR - 18, SANPADA, NAV! MUMBAI - 400705 BLUE JET T : 022- 41840550 / 40037603 F : +91 22 27814204 HEAUTREARE, E: sales@bluejethealthcare.com | CIN NO. : L99999MH1968PLC014154 May 27, 2024 To, BSE L
Slide 2: Investor Presentation Q4 & FY24
© BLUE JET HEALTHCARE TL Investor Presentation Q4 & FY24
Slide 3: Disclaimer
Disclaimer vencncrestsvinestssuannassnuannssssuanansssssnnsseunensssusnasesissnassssuaasnssnunnnesesiannessnuaseaseunnssesisnsnsssunnssssssunsessisnesssinnasssnnasessssassesisensese ee® The Presentation is to provide the general background information about the Company’s activities as at the date of
Slide 4: Contents
Contents Q4 & FY24 Financials WM ENOowWAWNE Company at a Glance Contrast Media Intermediates High Intensity Sweeteners Pharma Intermediates & API R&D Capabilities Growth Strategy Management and Board of Directors Investment Rationale
Slide 5: 1. Q4 & FY24 Financials
1. Q4 & FY24 Financials
Slide 6: Q4 & FY24 Earnings Highlights
Q4 & FY24 Earnings Highlights Financial Highlights Q4FY24 Vv Revenue from operations for Q4FY24 stood at Rs. 1,839 mn which de-grew 15.3% on YoY basis compared to Rs. 2,173 mn in QAFY23. Vv EBITDA for the quarter came at Rs. 531 mn, which was down 24.5% YoY compared to Rs. 703 mn in Q4FY23. Vv EBITD
Slide 7: Q4 & FY24 Earnings Highlights
Q4 & FY24 Earnings Highlights ee@ Financial Highlights FY24 v Revenue from operations for FY24 stood at Rs. 7,116 mn compared to Rs. 7,210 mn in FY23 v EBITDA for FY24 came at Rs. 2,292 mn up 4.6% YoY compared to Rs. 2,190 mn in FY23. v EBITDA margin for FY24 was at 32.2% as compared to 30.4% in FY2
Slide 8: FY24 Business Highlights
FY24 Business Highlights susessucssvessvessvesssessssessecsssesssesavecssessvesressusesasessssasessussavessuessneesssssssssssesssessvesauessnessucassessasesssssasesssessnessneasesssseceusesseessuessessvesseeensecsucesseeeasenseee ee® Business Highlights ¥ Launch took place in the PI/API product cate
Slide 9: Q4FY24 Vs Q4FY23 Financial Performance — Key Metrics
Q4FY24 Vs Q4FY23 Financial Performance — Key Metrics Revenue from Operations — Growth Trends (Fs Mn) YoY Growth: (33.0%) | ——> — — — (15.3%) wm Q4FY23 mQ4FY24 2,163 1,831 1,668 7 15 Contrast media intermediates High-intensity sweetners Pharma intermediates and API Others Total EBITDA Margin & EBITDA
Slide 10: FY24 Vs FY23 Financial Performance — Key Metrics
FY24 Vs FY23 Financial Performance — Key Metrics Revenue from Operations — Growth Trends (Fs Mn) YoY Growth: (5.3%) —— ——— 178.8% ——— 245.9% ——— mFY23 mFY24 7,185 7,084 5,070 4,799 1,759 4,282 947 —— ts ®s Contrast media intermediates High-intensity sweetners Pharma intermediates and API Others Tota
Slide 11: Profit and Loss Statement
Profit and Loss Statement Particulars (Rs. Mn) Q4FY24 Q4FY23 eka ey! Cost Of Goods Sold 860 1,004 709 3,144 3,360 Gross Margin 53.3% 53.8% 57.5% 55.8% 53.4% Employee benefits expenses 141 112 130 532 419 Other expenses 308 354 283 1,148 1,240 Total Expenses 1,309 1,470 1,122 4,824 5019 EBITDA Margin
Slide 12: Financial Performance over the years — Key Metrics
Financial Performance over the years — Key Metrics Revenue from operations — Growth Trends | (as un) FY21-24 CAGR: 10.7% ———> ———> | 31.4% —_—> 245.4% | —————> 12.8% MFY21 MFY22 MFY23 MFY24 6768 7185 7,084 4,778 5970 4799 1,575 1,759 1,282 947 340 133 3 16 55 Contrast media intermediates High-intens
Slide 13: Financials for the last three years
Financials for the last three years Summary Statement of Profit and Loss Summary Statement of Assets and Liabilities Particulars (Rs. Mn) eae aCe aCe} ae Particulars (Rs. Mn) a eel 7 FY23 Pe) 1. Assets Revenue from Operations 4,989 6,835 7,210 7,116 Property, plant and equipment 1,188 1,185 1,282 Ot
Slide 14: Shareholder Information
Shareholder Information Shareholding as on 31%t March 2024 Share Information as on 31st March 2024 NSE Ticker BLUEJET Others 8.9% BSE Ticker 544009 Other Dils MF 14% 1.7% Market Cap (INR Cr) 6,634 Fil % free-float 14% 2.0% Free-float market cap (INR Cr) 929 Cash & Cash Equivalents (INR Mn) 410 Share
Slide 15: 2. Company at a Glance
2. Company at a Glance
Slide 16: Our Journey
Our Journey B® Acquisition of greenfield site in Ambernath (Unit IV) m Received USFDA on a leasehold basis Establishment Inspection Report of Blue Circle Organics Private Limited for Unit II @ Established Blue @ Supply of Pharmaceutical ; m Entered the X-ray Circle : Organics : Intermediate toan m E
Slide 17: Who we are
Who we are A specialty pharmaceutical and healthcare ingredient and intermediate company, offering w T Teed MM Mfaate TN velco nlel ( ‘Collaboration, Development, Manufacturing” to CDMO business 16
Slide 18: Blue Jet Healthcare at a glance
Blue Jet Healthcare at a glance Key metrics 46: 1,020.90x. INR7,115.99mn INR2,292.30mn Commercialized product reaction capacity across . Revenue portfolio (FY24) 3 facilities (FY24) (FY24) (FY24) (12.6% (12.6% FY21-24 CAGR ) EBITDA (FY24) (FY24) (32.2% (32.2% margin margin) INR 847.06 mn 26.01% 21.4
Slide 19: Overview of our Product Categories
Overview of our Product Categories [eka (Cem U elem anda telr te) S High Intensity Sweeteners Pharma Intermediates & APIs ™@ Contrast media are agents used in medical imaging to @ High-intensity sweetener business involves @ Collaboration with innovator pharmaceutical enhance the visibility of body
Slide 20: 3. Contrast Media Intermediates
3. Contrast Media Intermediates
Slide 21: Overview of Contrast Media and its growth drivers
Overview of Contrast Media and its growth drivers What is contrast media? Types of contrast media ™ Chemical agents that enhances the contrast of an imaging modality in diagnostic . . a . . . = X-ray / Computed Tomography (CT) contrast agents: iodine-based contrast media imaging, thereby aiding diag
Slide 22: The global Contrast Media industry is highly concentrated
The global Contrast Media industry is highly concentrated Global Contrast Media competitive landscape ee@ Player 1 4) Highly concentrated and dominated by multi-national 17% Others corporations, 25% Total value Player 2 USS5.9bn (MAT Jun 2023) 20% 4) Collectively hold “75% of the global sales of con
Slide 23: High entry barriers for key intermediates' vendors
High entry barriers for key intermediates’ vendors Characteristics of the Contrast Media market Blue Jet's positioning Contrast Media Intermediate product category performance In INRmm Vv More than two decades of experience ict i l f > snphicellnane panei V¥ 75%+ of exports of a selected contrast me
Slide 24: Key benefits
Key benefits Strong product development and process optimization capabilities underpinned by in-house R&D capabilities @ Y Capture larger wallet share with ie existing customers \e/ Focus on molecules with customer interest and —~. strategy in either outsourcing or alternate sourcing PT the next sta
Slide 25: 4. High Intensity Sweeteners
4. High Intensity Sweeteners
Slide 26: Blue Jet's positioning in High Intensity Sweetener
Blue Jet’s positioning in High Intensity Sweetener Blue Jet's positioning High Intensity Sweeteners product category performance Revenue (INR mn) [Prod ucts @ Adherence to strict internal standards to ensure consistency in quality, performance, taste, and Vv impurity profile CAGR: 9.1% @ Multiple pr
Slide 27: 5. Pharma Intermediates & API
5. Pharma Intermediates & API
Slide 28: Trends and features of the Pharma Intermediates and APIs Product Category
Trends and features of the Pharma Intermediates and APIs Product Category ° e Features of a typical arrangement to supply of intermediates to Key trends in Pharma Intermediates and CDMO market innovators of NCEs r @t® Increased propensity to outsource manufacturing of intermediates & APIs Revenue an
Slide 29: Overview of Blue Jet's Pharma Intermediates and APIs Product Category
Overview of Blue Jet’s Pharma Intermediates and APIs Product Category e0e@ Commenced manufacturing pharma intermediates two decades Pharma Intermediate and APIs product category performance ago, leveraging the customer relationships through high-intensity In INR mn sweetener business Key focus areas
Slide 30: Leverage long-standing customer relationships to enter adjacencies in pharma intermediates and API
Leverage our long-standing customer relationships to continue entering adjacencies in the pharma intermediate and API category °e@ Focus on three niche areas in providing CDMO services Blue Jet’s positioning Investigational new drugs and new chemical entities (NCEs) ™ Develop advanced intermediates
Slide 31: 6. R&D Capabilities
6. R&D Capabilities
Slide 32: Our R&D framework
Our R&D framework capabilities across Process research , , Process scale-up and Regulatory filings and Portfolio evaluation Process development P 8 ry 8 validation approvals Analytical research Chemistry research . Method development Characterization of Polymorphism screening Pharmaceutical salt . .
Slide 33: Sustainability
Sustainability Various initiatives on energy efficiency, renewable energy, and water conservation to reduce carbon footprint Invested in windmills with installed capacity of 3.3MW Created carbon sinks through tree plantations \ Y ei Focus on enhancing energy efficiency Effluent treatment plants with
Slide 34: 7. Growth Strategy
7. Growth Strategy
Slide 35: Our strategies
Our strategies senstntnetstostits pnvnevntineintinetntinetnietnetntneintietntintntintinstntietineietinetntinetiniietniinenaintietntietneistineineinetineietneestneeneineenee ee® Focus on operational efficiency and O Continue to forward integrate into more mitigation of supply chain risks OC} advanced
Slide 36: 8. Management and Board of Directors
8. Management and Board of Directors
Slide 37: Experienced and visionary management team backed by independent Board of Directors
Experienced and visionary management team backed by independent Board of Directors Management team Akshay Bansarilal Arora Shiven Akshay Arora Executive Chairman Managing Director ™@ Has more than three decades of experience with the Company ™@ Has more than six years of experience with the Company
Slide 38: Management team and independent board of directors (cont'd)
Experienced and visionary management team backed by independent Board of Directors (cont’d) Management team (cont’d) a Sweta Poddar Company Secretary and Compliance Officer ™ Has experience of over a decade as a company secretary @ Associated with Chinar Chemicals Private Ltd. and Aarey Drugs and Ph
Slide 39: 9. Investment Rationale
9. Investment Rationale
Slide 40: Investment Rationale
Investment Rationale 1. Large manufacturer of contrast media intermediates in India Cay 2. Presence in niche categories with high barriers to entry RQ 3. Long-standing relationships and multi-year contracts with multi-national customers BLUE JET G 4. Strong product development and process optimizati
Slide 41: Thank You
Thank You May 2024 BLUE JET HEALTHCARE LIMITED INVESTOR RELATIONS AT Registered Office Blue Jet Healthcare Limited 701,702, 7th Floor, Bhumiraj Costarica, @) Sanjay Sinha, Deputy Chief Financial Officer Sector 18, Sanpada, Navi Mumbai Thane sanjay.sinha@ bluejethealthcare.com 400705, Maharashtra, In